KORU Medical Systems: A New Era Begins

On a call that was as much about the past as it was about the future, KORU Medical Systems President and CEO Linda Tharby marked her last earnings presentation as the company's leader, while also introducing Adam Kalbermatten, the company's new Chief Commercial Officer, as her successor.

Tharby's five years at the helm of KORU have seen significant growth and progress for the company, including a strong position in large volume drug delivery. She expressed pride in what had been accomplished during her tenure, citing the strength of the business and an exceptional team that would continue to drive the company forward.

In a surprise announcement, Tharby revealed that she would be retiring as CEO effective June 13th, with Kalbermatten taking over on July 1. The transition was described as 'smooth and seamless,' with Tharby committing to remain on the board through the end of 2026 in an advisory capacity.

Kalbermatten brings a wealth of experience from his career spanning over 20 years, including time at large med tech companies and stints as CEO. He has demonstrated strategic discipline and commercial leadership, earning the trust of investors and industry partners alike. As he prepares to take the reins, Kalbermatten expressed confidence in KORU's growth potential, citing the strength of the executive team and a combined 115 years of experience.

For KORU shareholders and customers, the change at the top is sure to be closely watched. The company has seen significant progress under Tharby's leadership, but investors will now turn their attention to Kalbermatten and his plans for the future.

As the company looks ahead, it remains committed to its growth strategy, driven by a strong team with a proven track record of delivering results. With Kalbermatten at the helm and Tharby providing guidance in an advisory capacity, KORU Medical Systems is poised to take on new challenges and push forward into a bright future.